NCT lookup

Key Inclusion criteria

* Participants with confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.
* Participants must have platinum-resistant disease:
* Participants who have only had one prior line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (CR or PR) and then progressed between \> 3 months and ≤ 6 months after the date of the last dose of platinum.
* Participants who have received 2 or 3 lines of platinum therapy must have progressed ≤ 6 months after the date of the last dose of platinum.
* Participants must have radiologically progressed on or after their most recent line of therapy.
* Participants must have received at least one, but no more than 3, prior systemic lines of anti-cancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment
* Participants with documented BRCA mutation (germline and/or somatic) must have received prior PARPi if the participant is eligible per approved label and standard-of-care institutional guidelines, except in cases of documented contraindication, precaution or intolerance.
* Provision of an FFPE tumour tissue sample

Key Exclusion criteria

* Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumours containing any of the above histologies, or low-grade or borderline ovarian tumour.
* Primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤ 3 months after the last dose of first line platinum-containing chemotherapy.
* Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring
* Current signs, symptoms, or clinical investigations consistent with bowel obstruction, including sub-occlusive disease.
* Participant has non-infectious ILD/pneumonitis or has a history of non-infectious ILD/pneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
* Prior treatment with any FRα-targeted therapy, including MIRV, or any TOP1i ADC.
* Major surgical procedure within 4 weeks of the first dose of study intervention

• Birmingham, Alabama, United States
• Little Rock, Arkansas, United States
• La Jolla, California, United States
• Washington D.C., District of Columbia, United States
• Fort Lauderdale, Florida, United States
• Gainesville, Florida, United States
• Jupiter, Florida, United States
• Miami, Florida, United States
• Weston, Florida, United States
• Chicago, Illinois, United States
• Evanston, Illinois, United States
• Peoria, Illinois, United States
• Urbana, Illinois, United States
• Fort Wayne, Indiana, United States
• Indianapolis, Indiana, United States
• Louisville, Kentucky, United States
• Towson, Maryland, United States
• Burlington, Massachusetts, United States
• Worcester, Massachusetts, United States
• Minneapolis, Minnesota, United States
• Springfield, Missouri, United States
• Billings, Montana, United States
• Omaha, Nebraska, United States
• Las Vegas, Nevada, United States
• Lebanon, New Hampshire, United States
• Camden, New Jersey, United States
• The Bronx, New York, United States
• Chapel Hill, North Carolina, United States
• Blue Ash, Ohio, United States
• Dayton, Ohio, United States
• + 269 more on CT.gov